<DOC>
	<DOCNO>NCT00779935</DOCNO>
	<brief_summary>This Phase 4 , multi-center , open-label , one-arm , pilot study patient active ankylose spondylitis refractory conventional treatment . Remicade give Weeks 0 , 2 , 6 every 8 week Week 54 . The number patient show ASAS-20 clinical response Week 14 evaluate .</brief_summary>
	<brief_title>Growth Factor Concentration Predict Ankylosing Spondylitis Patient 's Response Infliximab ( Study P04041 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Diagnosis ankylose spondylitis proven appropriate diagnostic method ( accord New York criterion ) . Refractory disease define failure least 2 nonsteroidal antiinflammatory drug ( NSAIDs ) 3month period failure sulfasalazine subject associate peripheral arthritis . Active disease define : sustain BASDAI least 40 0100 scale expert opinion base clinical feature . Age 18 70 year . Subjects use NSAIDs and/or sulfasalazine must stable dose least 4 week prior study initiation , may continue medication treatment period , dose must increase baseline . Subjects must capable demonstrate willingness participate study comply procedure sign write informed consent . Men woman childbearing potential ( include woman less 1 year postmenopausal woman become sexually active ) must use acceptable method birth control ( eg , hormonal contraceptive , medically prescribe IUD , condom combination spermicide ) surgically sterilize ( eg , hysterectomy tubal ligation ) . Subjects must understand able adhere dose visit schedule . Subject moderate severe heart failure ( NYHA class III/IV ) . Remicade must give subject history hypersensitivity infliximab , murine protein , excipients . Subjects preexist recent onset central nervous system demyelinate disorder . Age &lt; 18 &gt; 70 year . Pregnant woman , nurse mother . Subjects incapacitate , largely wholly bedridden confine wheelchair , little ability selfcare . Subjects current systemic inflammatory condition sign symptom might confound evaluation benefit infliximab therapy . Prior administration infliximab therapeutic agent target reduce TNF ( eg , Etanercept , pentoxifylline , thalidomide antiCD4+ antibody ) . Current treatment systemic corticosteroid . Treatment investigational drug within previous 3 month . History known allergy murine protein . Subjects active inactive tuberculosis ( TB ) . All subject must evaluate active inactive ( 'latent ' ) TB . This evaluation include detailed medical history personal history TB possible previous contact TB previous and/or current immunosuppressive therapy . Appropriate screening test ( ie , tuberculin skin test chest xray ) perform subject . Serious infection , sepsis , abscess , hepatitis , pneumonia , pyelonephritis previous 3 month . Less serious infection previous 3 month , acute respiratory tract infection ( cold ) uncomplicated urinary tract infection need consider exclusion discretion treat physician . History opportunistic infection herpes zoster within 2 month study initiation . Evidence active CMV , active pneumocystis carinii , drug resistant atypical mycobacterium , etc . Documented HIV infection . Current sign symptom severe , progressive uncontrolled renal , hepatic , hematologic , endocrine , pulmonary , cardiac , neurological , cerebral disease . Any currently know malignancy premalignant lesion history malignancy within past 5 year ( except nonmelanoma skin cancer surgically cure cervical cancer ) . Subjects alcoholism , alcoholic liver disease , chronic liver disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>